It's an "editorial" and in lieu of the abstract, here's the free first 150 words of the text:
The significance of antibodies induced by therapeutically administered formulations of recombinant human interferon β (IFN-β) in multiple sclerosis (MS) has been a controversial topic since it was first reported in association with IFN-β-1b in 1993.1 Indeed, all current formulations of IFN-β are immunogenic (but in varying degrees) such that high titers of induced IFN-β neutralizing antibodies (NAb) do in fact neutralize in vitro IFN-β bioactivity. With regard to all currently available IFN-β—despite early, inconclusive, and often opposing studies—review of the world literature on this topic has allowed task forces of the European Federation of Neurological Societies2 and the American Academy of Neurology3 to agree on several important conclusions:
The presence of NAb, especially in persistent high titers, is2 (or, probably is3) associated with reduction of clinical and magnetic resonance imaging–based effectiveness of IFN-β treatment.
All currently available IFN-β formulations induce NAb in IFN-β–treated persons with MS.
Author Affiliation: Multiple Sclerosis Center at Texas Neurology and Baylor Institute for Immunology Research, Dallas.